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Erlotinib or Docetaxel for Second-Line Treatment of
Non-small Cell Lung Cancer
A Real-World Cost-Effectiveness Analysis
Ian Cromwell, MSc,* Kimberly van der Hoek, MSc,* Barbara Melosky, MD,†
and Stuart Peacock, MSc*‡
Introduction: Erlotinib was recently approved in British Columbia
(BC) as a second-line treatment for advanced NSCLC. A cost-
effectiveness analysis was conducted which compares costs and
effectiveness in patients who received second-line erlotinib with
those in patients who received docetaxel.
Methods: In a population of patients who have been treated with
drugs (either erlotinib or docetaxel) for advanced NSCLC, overall
survival (OS), progression-free survival (PFS), and probability of
survival 1 year after beginning of second-line treatment (1YS) were
determined using Kaplan-Meier and Cox proportional hazard anal-
ysis, as well as 2 test. Costs were collected retrospectively from the
perspective of the BC health care system.
Results: Incremental mean OS was 1 day, and incremental mean
cost was $2891. Neither costs nor effectiveness were statistically
significantly different between groups. PFS and 1YS were also
nonsignificantly different. Cox proportional hazard models were
used to evaluate multivariate confounding.
Conclusions: Erlotinib and docetaxel are statistically equivalent in
terms of treatment cost and overall survival. As treatment practice
patterns change, docetaxel may become more frequently prescribed.
Therefore, the choice of whether to use erlotinib or docetaxel should
be based on factors relating to patient preference rather than costs or
effectiveness.
Key Words: Health economics, Cost-effectiveness, Lung cancer,
Erlotinib, Docetaxel, Real-world, Retrospective analysis.
(J Thorac Oncol. 2011;6: 2097–2103)
Lung cancer is the number one cause of cancer death inCanada, representing more than 25% of all cancer deaths.1
In British Columbia (BC), Canada, 1250 people died of lung
cancer in 2009.1 Advanced-stage lung cancer (stage IIIb/IV)
is commonly treated palliatively, meaning that the intention is
to prolong life rather than to cure the disease.2 Treatment of
this kind in BC is accomplished through a number of che-
motherapeutic agents and radiation therapy. Chemotherapy is
administered according to BC Cancer Agency (BCCA) pro-
tocols, with various regimens available across multiple stages
(lines) of therapy.
Erlotinib (trade name Tarceva, Hoffmann-La Roche/
OSI Pharmaceuticals/Genentech) is a tyrosine kinase inhibi-
tor affecting the expression of epidermal growth factor in
lung tumors. A large randomized clinical trial found an
overall survival benefit of 2.0 months in patients treated with
erlotinib compared with placebo.3 Erlotinib was also found to
improve tumor-related symptoms and overall quality of life.4
A retrospective analysis of Canadian hospital data conducted
by Melosky et al.5 found that erlotinib is well tolerated as an
explicitly second-line treatment, particularly in patients with
an East Asian ethnic background.
Recently, the BCCA began funding erlotinib for use as
second-line treatment of advanced non-small cell lung cancer
(NSCLC).6 Unlike docetaxel (trade name Taxotere, Sanofi-
Aventis)—another available metastatic lung cancer treatment
that is administered intravenously—erlotinib is taken orally,
with patients undergoing diagnostic testing before each treat-
ment cycle to ascertain the presence or absence of tumor
progression.
Our pragmatic study investigated the cost-effectiveness
(CE) of the second-line erlotinib protocol compared with
docetaxel in BCCA patients.
PATIENTS AND METHODS
Patients
Eligible patients were patients treated at the BCCA with a
diagnosis of stage IIIb/IV advanced NSCLC who received
second-line treatment between September 1, 2005, and March
31, 2008 (including adenocarcinoma, NSC carcinoma, squa-
mous cell and large cell carcinomas, bronchioloalveolar carci-
noma, and lung carcinomas not otherwise specified). Patients
were classified into one of the two groups: those having had at
least one prescription filled for erlotinib (treatment group) or
those receiving docetaxel (comparative group) as second-line
treatment. The observation period corresponds to the date from
*Canadian Centre for Applied Research in Cancer Control (ARCC); †British
Columbia Cancer Agency; and ‡School of Population and Public Health,
University of British Columbia, Vancouver, British Columbia, Canada.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Ian Cromwell, MSc, 2nd Floor, BC Cancer
Research Centre, 675 West 10th Avenue, Vancouver BC V5Z 1L3
Canada. E-mail: icromwell@bccrc.ca
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0612-2097
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 2097
which erlotinib was funded by the BCCA for second-line treat-
ment to the last day that data were available.
Per BCCA protocol, 150 mg erlotinib is taken orally on
a daily basis until evidence of disease progression, at which
time erlotinib is discontinued.6 The other docetaxel (75 mg/
m2) is administered intravenously every 21 days for six
cycles or until evidence of progression.7 Patients are evalu-
ated for response before each cycle (1 month for erlotinib; 21
days for docetaxel). Dose modification is determined based
on adverse effects as outlined in their respective protocols.
Patients were excluded from either group if they had
another nonlung cancer diagnosis (with the exception of
nonmelanoma skin cancers) within 5 years before a diagnosis
of lung cancer; if they were enrolled in a clinical trial; if they
filled only one prescription for second-line therapy (i.e., did
not complete one cycle); or if they received erlotinib as
first-line treatment. Line of therapy was determined accord-
ing to BCCA therapeutic protocol codes.
Study Design
A retrospective medical record review was performed.
Date, type of chemotherapy, number of cycles, and number of
lines of chemotherapy were obtained from records kept by the
BCCA Provincial Systemic Therapy Program. Age, sex, date
of death, and number/type of appointments and tests received
in BCCA Cancer Centers were collected using the electronic
BC Cancer Agency Information System (CAIS). Data on
hospitalization and Resource Intensity Weights, provincially
insured medical services (according to the Medical Sevices
Plan), outpatient prescription drugs (PharmaCare), and Home
and Community Care (HCC) were provided by the provincial
Ministry of Health Services.
Date of progression after second-line treatment, defined
as the earliest date at which the responsible oncologist iden-
tifies progression of lung disease, was determined from re-
view of electronic patient charts. These charts were also used
to determine smoking status (from physician notes) and
ethnic background (East Asian ethnic background versus
other ethnic background by last name). Costs and effective-
ness were both restricted to the time frame of September 1,
2005, to March 31, 2008.
The primary outcome was the cost-effectiveness (CE)
of erlotinib based on mean overall survival (OS), calculated
as the area under Kaplan-Meier survival function (AUC)
from the beginning of second-line treatment to death. Sec-
ondary outcomes were CE based on progression-free survival
(PFS) and 1-year overall survival (1YS). 1YS was a dichot-
omous variable based on a patient’s status (alive or dead) at
1 year after the beginning of second-line treatment. Survival
was censored if the patient was alive at the end of the
observation period.
This study was conducted from the perspective of the
provincial health care system, and the CE analysis was per-
formed using the total cost of all health resources (including
drug, labor, and supply costs) used by the cohort of patients from
the beginning of second-line treatment to death (or censoring).
As the study was retrospective, future costs were not calculated
and discounting was therefore not appropriate.
Statistical Analysis
OS and PFS were assessed according to a Kaplan-Meier
survival analysis with 95% confidence intervals. Statistical sig-
nificance was determined according to the Wilcoxon statistical
test. Cox proportional hazard models were constructed to test the
effect of covariation and control for confounding, expressing
relative risk of death as a hazard ratio (HR). Treatment line was
forced into the model, while all other variables were evaluated
according to backward elimination. The proportions for 1YS
were calculated using a 2 test for significance.
CE analyses to determine the incremental cost-effec-
tiveness ratio (ICER) of erlotinib versus all other second-line
treatments were based on the difference in mean cost of the
two treatments divided by the difference in outcomes (Ce 
Cc/Ee  Ec). Costs are measured in 2009 Canadian dollars.
Effectiveness was measured as the area under the Kaplan-
Meier survival curve, expressed as incremental life years
gained (LYG) due to difference in treatment. Univariate
sensitivity analysis was performed on costs and effectiveness,
allowing inputs to vary from the maximum to the minimum
for costs, and over the 95% CI of survival for outcomes.
Probabilistic sensitivity analysis was performed for ICERs,
using Monte Carlo sampling from the distribution of costs
and effectiveness.
A sample size calculation was not performed as the
entire population eligible within the described timeframe was
included. Power was calculated post hoc. Analysis software
included Microsoft Excel and SAS 9.1 statistical software.
RESULTS
Patient Characteristics
Four hundred seventy-seven patients filled prescrip-
tions for erlotinib or docetaxel from the BCCA within the
study time frame. Once patients in clinical trials (n  182),
those receiving gefitinib (n  3), with more than one cancer
diagnosis (n  52), received only one cycle of second-line
treatment (n  34), or who received care that did not
correspond to a BCCA protocol (four patients received first-
line erlotinib, one patient received gemcitabine as second-line
treatment) were removed, a cohort of 201 eligible patients
was identified. Of these, 133 received erlotinib as second-line
treatment while the remaining 68 received docetaxel.
Outcomes
Table 1 outlines the outcomes data. Clinical outcomes
are described in Table 2, while time-to-event data are pre-
sented in Figures 1 and 2. It should be noted that not all
patients in the sample received second-, third-, and fourth-
line therapy—the presented costs are the mean values for
those who received treatment.
The survival analysis had 79.2% statistical power (two-
tailed,   0.05). Patients receiving erlotinib did not expe-
rience a statistically significant survival advantage over those
receiving docetaxel as second-line therapy, either in terms of
overall or progression-free survival. Cox proportional hazard
analysis found no significant associations between treatment
type and overall survival when controlling for sex, diagnosis
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date, and smoking status as well as multiplicative interaction
terms thereof.
Adenocarcinoma was significantly statistically associ-
ated with longer PFS in the Cox analysis when compared
with other malignant cell types (HR  0.661, p  0.021),
irrespective of treatment modality. To investigate the impact
this statistical finding may have had on the outcome of
interest, patients with an adenocarcinoma were analyzed
separately. Patients treated with docetaxel had mean PFS
equal to 122 days (n  22, SD  28 days), while patients
treated with erlotinib had PFS equal to 47 days (n  62,
SD 4.6 days); however, this difference was not statistically
significant (p  0.868). Age was also a predictive factor for
PFS (HR  0.973, p  0.001), but the effect of treatment
type was unchanged when age was controlled for.
Costs
The value of resources consumed by patients in each
cohort was compared using their historical charts from the
perspective of the BC health care system and expressed in
2009 Canadian dollars (CDN). These resources include the
cost of chemotherapeutic drugs; radiation therapy; physi-
cian appointments and diagnostic tests covered by the
provincial Medical Services Plan; drugs covered under the
provincial PharmaCare plan, HCC; and resource costs due to
hospitalization, measured according to Resource Intensity
Weights and converted to costs using hospital-specific mean
case costs.
Reported mean costs are those experienced by patients
who used the services (e.g., patients who did not receive
radiotherapy are not reflected in the average cost of radio-
therapy). As described in Table 2, overall costs did not differ
significantly between the two groups. Patients receiving er-
lotinib had higher drug costs than those receiving docetaxel,
but fewer patients in that group received third- or fourth-line
treatment. Costs in the other categories were not significantly
different between groups (according to Student t test). Mean
total cost/patient was $35,708 and $32,817 in the erlotinib
and docetaxel groups, respectively. This difference is not
statistically significant.
Component costing suggests that second line drugs
comprise 42% of costs in the erlotinib group, while third-
line drugs representing only 6%. This is contrasted with
the docetaxel group, where second-line drugs, third-line
drugs, and hospitalization each make up about 25% of total
cost. Proportional costs in both groups are presented in
Figure 3.
TABLE 1. Demographics and Baseline Characteristics
Parameter
Erlotinib
(N  133)
Docetaxel
(N  68)
Median, age (range), yra 65 (39–88) 64 (45–77)
Sex, male, n (%)b 56 (42.1) 36 (52.9)
Smoking status (%)b
Never-smokers 14.7 22.6
Quit 15 yr ago 13.2 20.3
Quit 15 yr ago 22.0 18.0
Still smoking 44.1 28.6
Status unknown 5.9 10.5
Fractions of RT (SD) 2.50 (4.31) 2.40 (5.27)
p  0.05.
a Mann-Whitney U test.
b Fisher’s exact test.
TABLE 2. Clinical Outcomes Results and Costing Data
Parameter Erlotinib (N  133) Docetaxel (N  68)
Median OS (95% CI), d 251 (44–762) 225 (166–310)
Mean OS (95% CI)a, d 311 (264–344) 310 (248–333)
Difference 1 d
Median PFS (95% CI), d 34 (29–43) 30 (25–49)
Mean PFS (95% CI)a, d 64 (61–66) 75 (43–77)
Difference 11 d
1-yr OS (%) 36.1 32.4
Mean cycles/patient, n (range) 6.2 (2–32) 4.0 (2–8)
Mean drug cost/patient (range), $
Second line, N  133; 68 14,975 (12,581–17,368) 6,218 (5,541–6,894)
Third line, N  29; 67 12,919 (8,920–16,918) 7,847 (5,892–9,711)
Fourth line, N  7; 7 4,443 (0–13,249) 2,132 (0–4,328)
Mean radiotherapy cost/patient (range), $; N  50; 23 2,168 (325–6,835) 2,307 (325–11,391)
Mean MSP-billable services (range)b, $; N  133; 68 2,802 (151–11,600) 3,295 (247–11,671)
Mean PharmaCare cost/patient (range)b, $; N  120; 65 3,389 (116–23,730) 3,927 (152–24,475)
Mean HCC cost/patient (range)b, $c; N  31; 6 5,241 (35–51,293) 3,450 (6–18,920)
Mean hospital cost/patient (range), $; N  103; 56 12,587 (411–64,243) 12,664 (995–49,007)
Mean overall cost/patient (95% CI), $; N  133; 68 35,708 (32,241–39,174) 32,817 (27,940–37,693)
Difference $2,891
a Area under curve (AUC) of Kaplan-Meier time-to-event function.
b Data provided by the British Columbia Ministry of Health.
c p(Satterthwaite)  0.036.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Erlotinib or Docetaxel for Second-Line Treatment of NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 2099
Cost-Effectiveness
As neither costs nor effectiveness were significantly
different between the two groups, it was not possible to
calculate a meaningful ICER (numerator and denominator
both indistinguishable from zero). Similarly, univariate sen-
sitivity analysis results in either a numerator of zero or a
denominator of zero and thus could not be performed.
A Monte-Carlo simulation was conducted wherein
costs and effectiveness of 1000 hypothetical members from
each group were allowed to vary according to their respective
underlying variances. This kind of “bootstrapping ” approach
permits examination of the effects of statistical uncertainty on
ICER estimates. This is considered a good practice for health
economic evaluations. ICERs were calculated from the out-
FIGURE 1. Kaplan-Meier estimates of overall survival of erlotinib and comparative groups.
FIGURE 2. Kaplan-Meier estimates of progression-free survival in erlotinib and comparative groups.
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put of this simulation to investigate the distribution of ICERs
around the null hypothesis (incremental costs and effective-
ness equal to zero). A plot from this output is displayed in
Figure 4.
Figure 4 suggests that there is no discernible pattern to
cost-effectiveness in these groups—there is no evidence from
this plot to suggest that erlotinib is more/less costly or
more/less effective than docetaxel. A reference cost-effec-
tiveness “threshold” of $50,000/LYG is included to illustrate
the level below which some health authorities may consider
funding of a new technology over another acceptable. Those
points that fall below the line are considered “cost-effective”
at that threshold. Figure 5 describes the percentage of ICERs
that fall below a variety of cost-effectiveness thresholds. As
many of the sampled ICERs had negative incremental effec-
tiveness (erlotinib yielded shorter survival, costs were either
more or less than comparative), comparatively few ICERs
were below a threshold as high as $1 million.
DISCUSSION
The purpose of this study was to examine the costs,
outcomes, and cost-effectiveness of erlotinib compared with
docetaxel in the second-line treatment of advanced-stage
NSCLC. Our analysis found that not only was progression-
free and overall survival statistically nonsignificantly differ-
ent between the two groups under study but also the overall
cost of treatment was similar. This result seems to suggest
that second-line treatment with erlotinib or docetaxel are
equally cost-effective and that factors other than survival and
economic efficiency should be considered when making a
decision about what method of treatment to pursue.
The chief difference between the two groups was the
relative role of third-line therapy. Far fewer patients in the
erlotinib group went on to receive a third line of treatment
(21.8% in the erlotinib group compared with 98.5% in the
docetaxel group). It is not possible to determine from our data
why this would be the case—logistic regression finds no
significant association between receiving third-line therapy
and any of the other variables in the analysis. It may be
possible that change in physician practice patterns explains
some of the discrepancy, as practitioners adopt new medica-
tions into their regular practice. It may also be possible that
some patients who had not previously been eligible for
erlotinib due to reasons related to performance status were
switched to third line more quickly; however, there was no
statistical relationship found between date of diagnosis and
survival. It may be useful to investigate and see whether this
discrepancy between amount of third-line treatment follow-
ing erlotinib versus docetaxel is a unique phenomenon of the
BC population or more generally in the treatment of NSCLC.
Because the proportional costs of second- and third-line
treatments are more evenly distributed in the docetaxel group
than in the erlotinib group, the effect of the cost of this
therapy (usually third-line erlotinib) balances the disparity in
second-line cost between the groups.
We did not collect data on patient quality of life (QoL).
A previous study of patients receiving erlotinib showed
symptom reduction and resulting improvement in reported
QoL compared with placebo.4 A clinical trial of first-line
pemetrexed suggests that patients experience similar im-
provement in QoL as patients receiving gemcitabine (trade
name Gemzar, Eli Lilly), a common chemotherapeutic
agent,8 while a review of trials involving patients receiving
docetaxel suggests that QoL generally improves with this
FIGURE 3. Proportional costs in erlotinib and comparative
groups.
FIGURE 4. 1000 Monte-Carlo sampled incremental cost-
effectiveness ratios of erlotinib versus comparative group.
FIGURE 5. Percentage of incremental cost-effectiveness ra-
tios falling below cost-effectiveness thresholds.
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drug as well. Lee et al.9 compared second-line gefitinib (trade
name Iressa, AstraZeneca)—an oral tyrosine kinase drug similar
to erlotinib—with docetaxel and found comparable QoL im-
provement. Given that erlotinib has a remarkably different ad-
verse effect profile to that of docetaxel (or indeed, any intrave-
nous chemotherapy regimen), it may be worthwhile to explore
the impact these adverse effects have on QoL.
Strengths
The main strength of this form of analysis is that, rather
than being based on a tightly controlled experimental condi-
tions and homogeneous group of clinical trial participants,
this study was based on the “real-world” outcomes and costs
experienced by actual patients. While clinical trials are cru-
cial in establishing efficacy and controlling for extraneous
influences, they sometimes do so at the expense of estimating
effectiveness—that is, how a policy decision (such as approv-
ing erlotinib) actually impacts both the patients and the health
care system in the real world.
Limitations
We excluded patients who only received a single cycle
of second-line chemotherapy. When these patients are in-
cluded in the analysis, mean OS in the erlotinib group drops
from 311 to 272 days and from 310 to 293 days in the
comparative group. However, the difference between the
groups remains nonsignificant (p  0.310). It was not possi-
ble to determine why these patients only received a single
line, but review of patient charts suggests that the chief
reasons for such a phenomenon were failure to respond to
treatment, unmanageable adverse effects, and death within 1
month of beginning therapy.
Because patients either self-selected or (more likely)
physicians selected them into a given treatment arm, it is not
possible to state from this analysis alone whether erlotinib
differs in effectiveness from docetaxel. As an observational
study, the conclusions that can be made based on the above
findings are more limited than they would be for a random-
ized, double-blind, placebo-controlled clinical trial. However,
this study may be more representative of reality than such a
trial, because it more accurately reflects “real world” practice.
Our exclusion criteria represent our attempt to balance the
competing interests of internal and external validity.
Costs from this study cannot be readily extrapolated to
the systems of other countries—costs from the Canadian
health care system are not reflective of costs in, for example,
the United States. Differences in reimbursement of health
professionals, capital and drug purchase costs, and the role of
private insurers all affect the overall cost of health care and
differ across national and regional lines.
This analysis did not consider the impact EGFR and
other gene mutation testing would have on the prescription of
erlotinib. EGFR patients may respond more strongly to
drugs such as erlotinib than EGFR patients, meaning that
such genetic testing may direct more effective and personal-
ized treatment regimens. Prescribing targeted therapies to
patients likely to derive a greater benefit (and, conversely, not
prescribing therapies that are unlikely to work) should in-
crease treatment effectiveness while reducing the overall cost
to the health care system.
Comparison of Effectiveness to Literature
Efficacy
This study is the first attempt in the literature to explic-
itly compare the effectiveness of erlotinib and docetaxel in a
real-world setting. Shepherd et al., Fossella et al., and Hanna
et al. conducted clinical trials comparing docetaxel to best
supportive care (BSC),10 vinolrebine or ifosfamide,11 and
pemetrexed,12 respectively. The findings in these trials are
consistent with the survival outcomes found in this study.
Smit et al.13 found a median time-to-progression of 2 months
and median survival of 5.7 months in patients receiving
second-line single-agent pemetrexed. Shepherd et al.3 estab-
lished the efficacy of erlotinib compared with BSC and found
a median overall survival of 6.7 months in the erlotinib group.
However, this cohort included patients in both second- and
third-line contexts. As a result, it was not possible to establish
the efficacy of explicitly second-line erlotinib from this trial.
Melosky et al.5 conducted a retrospective review of 35
patients receiving second-line erlotinib and found a time-to-
progression (equivalent to PFS) of 7 months, dramatically
longer than the PFS found in this study. Ng et al.14 compared
retrospective outcomes in a cohort of patients who received
either erlotinib/gefitinib or docetaxel as second-line treatment
and found no significant difference in OS or PFS, with
median values of 52 and 288 days (erlotinib), respectively.
Median PFS and OS in the various studies, as well as
this one, are compared in Table 3. Our findings of equivalent
cost stand somewhat at odds with the findings in other
studies. Leighl et al.15 calculated a second-line treatment cost
of $22,800 (adjusted for inflation to CDN 2009); however,
this cost only includes resources consumed in hospital during
the clinical trial and neglects things such as community care.
Economic analyses in the United States,16,17 Portugal,18 and
Germany19 and a recent systematic review of the economic
literature on erlotinib20 found that, compared with docetaxel
and/or pemetrexed, erlotinib is less costly. Our study looked
at all health care system-reimbursed resource utilization from
the time of second-line treatment to death, the scope and costs
of which will differ between countries. In addition, our costs
TABLE 3. Literature Comparison
Study
Sample
Size
Docetaxel Erlotinib
PFS (d) OS (d) PFS (d) OS (d)
This study 231 30 225 34 251
Shepherd et al.10 104 74 213 N/A N/A
Fossella et al.11 373 59 201 N/A N/A
Smit et al.13 79 N/A N/A N/A N/A
Hanna et al.12 571 106 240 N/A N/A
Shepherd et al.3a 731 N/A N/A 67 204
Melosky et al.5 35 N/A N/A 213 N/A
Ng et al.14b 74 80 136 52 288
a Mix of second- and third-line patients.
b Patients received either erlotinib or gefitinib.
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were determined using administrative data from patients in
actual real-world practice. As such, our results may capture a
real effect that would be impossible to detect in clinical trials.
A recent cost-effectiveness analysis of the BR.21 clinical
trial cohort calculated a mean ICER of $67,844/LYG in patients
receiving second-line erlotinib.21 This cohort was randomized to
either erlotinib or placebo and BSC, and alternative second-line
therapies were not evaluated. As a result, the extent to which
comparisons can be made is limited. Costs in this trial were a
combination of second- and third-line treatments, which further
limits the value of comparisons; however, the mean costs for
drugs, diagnostic tests, radiotherapy, and hospitalizations were
higher in our study. It is worthwhile to note that the costs
experienced by patients in a “real-world” setting are likely to be
greater than clinical trials, in which the patient population can be
more tightly controlled.
CONCLUSIONS
Our analysis found that in terms of both costs and
effectiveness (overall survival and progression-free survival),
erlotinib and docetaxel are equivalent. It is not possible from
this analysis to know why patients receive one drug or
another. A willingness-to-pay study suggested that patients
prefer oral tyrosine kinase medications such as erlotinib to
intravenous chemotherapy but by a slim margin.22 Given that
physicians have a choice of treatments with equivalent effi-
cacy, their decision to prescribe one over another is likely
based on personal and patient preference rather than expected
outcomes or economic factors.
The BCCA recently began funding pemetrexed as a
first-line treatment for NSCLC on a maintenance schedule—
drugs are prescribed until progression—rather than stopping
after six cycles. Pemetrexed has emerged in many jurisdic-
tions as the most common second-line regimen. Gemcitabine,
another EGFR antagonist drug, is gaining mainstream accep-
tance as well. As these newer therapies gain popularity as
first- and second-line treatments for NSCLC, docetaxel may
emerge as a useful alternative and/or third-line treatment. The
above analysis suggests that physician and patient preference,
based on likelihood and severity of toxicity and ease of
administration, should guide the decision to use either erlo-
tinib or docetaxel—not economic or survival concerns.
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